Expiration date: 04/2026

Structure and Composition

Femoden - dragee:

1 dragee contains 0.075 mg of gestodene, ethinyl estradiol 0.03 mg Excipients: lactose monohydrate, corn starch, polyvidone 25000, sodium calcium edetate, magnesium stearate, sucrose, 70000 polyvidone, polyethylene glycol (macrogol) 6000, calcium carbonate, talc, waxes montanglikolevy .

in a blister pack with a calendar scale of 21 pcs., in box 1 blister.

pharmachologic effect

Femoden provides contraceptive estrogen-progestin action. It inhibits the secretion of FSH and LH by the pituitary gland. Inhibits follicle maturation and ovulation. Femoden reduces the susceptibility of the endometrium to the blastocyst, increases the viscosity of cervical mucus. It impedes the penetration of sperm into the uterus. There were no fetal malformations, fertility disorders, lactation and reproductive function of the offspring of animals previously treated with the drug. Investigation of ethinyl estradiol and gestodene in vitro and in vivo showed no mutagenic properties.

testimony

Contraception (prevention of unwanted pregnancy).

Contraindications

Hypersensitivity, severe liver dysfunction, liver tumors (including in history), thromboembolism (including history and an increased risk of its development, for example, disorders of blood clotting system with a tendency to thrombosis, certain heart diseases) severe diabetes with vascular complications, pancreatitis or a history, accompanied by severe hypertriglyceridemia, migraine with focal neurological symptoms in the history of breast cancer and endometrial (including history), uterine bleeding of unknown origin, pregnancy.